亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation

布鲁顿酪氨酸激酶 伊布替尼 慢性淋巴细胞白血病 癌症研究 化学 体内 药理学 酪氨酸激酶 信号转导 白血病 生物 生物化学 免疫学 遗传学
作者
Minke E. Binnerts,Kevin L. Otipoby,Brian T. Hopkins,Tonika Bohnert,Stig K. Hansen,Gene C. Jamieson,Pamela A. Howland,Eric H. Bjerkholt,Deborah A. Thomas,Judith A. Fox,Adam R. Craig
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:14 (12_Supplement_2): C186-C186 被引量:24
标识
DOI:10.1158/1535-7163.targ-15-c186
摘要

Abstract Background and purpose: BTK mediates B-cell receptor signaling and was validated as a target by the BTK inhibitor ibrutinib in several B-cell malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia (CLL). However, patients may have or acquire resistance. Resistance mechanisms include mutation of the cysteine in the BTK active site that ibrutinib requires for covalent binding (C481). We identified and characterized SNS-062, a potent, noncovalent BTK inhibitor with activity towards BTK harboring resistance mutations that also inhibits ITK and may provide enhanced anti-tumor immune responses. SNS-062 shows restricted kinase selectivity and nonclinical pharmacology, pharmacokinetics (PK) and toxicology profiles distinct from ibrutinib and merits clinical investigation. Methods and Results: In in vitro kinase binding assays, SNS-062 bound to 9 kinases with Kd < 25 nM, including Tec kinase family members BTK (0.3 nM) and ITK (2.2 nM), but did not bind EGFR. Lack of EGFR inhibition by SNS-062 may offer safety advantages over ibrutinib, which has been associated with diarrhea and rash potentially related to its off-target effects on EGFR. Cellular inhibition of BTK was demonstrated by measuring inhibition of BTK auto-phosphorylation. SNS-062 inhibited pBTK in human whole blood with an average IC50 of 50 nM. A PK/ PD (pBTK) relationship was demonstrated in mice, with an in vivo IC50 for pBTK inhibition of 47 nM. Prolonged SNS-062-mediated in vivo inhibition of pBTK correlated with potent efficacy in a T cell-independent (type II) BTK dependent B cell mediated antibody response mouse model (ED50 11 mg/kg); efficacy was also observed in a type II collagen- induced arthritis (CIA) rat model (ED50 for summed knee and ankle histopathology 0.8 and 3.9 mg/kg). To assess the activity of SNS-062 and ibrutinib against BTK with acquired resistance mutations, inhibition of wild type (WT) and mutant C481S BTK was evaluated in direct kinase assays. SNS-062 inhibited WT and C481S BTK with similar IC50s (pBTK IC50s: WT BTK 2.9 nM, C481S BTK 4.4 nM) while ibrutinib potency was reduced 40-fold (pBTK IC50s: WT BTK 0.58 nM, C481S BTK IC50 25.7 nM). Similarly, ibrutinib showed a 100-fold loss of potency in C481S BTK expressing 293 cells (pBTK IC50s: WT BTK 0.016 μM, C481S BTK 1.7 μM) while SNS-062 activity was unaffected (pBTK IC50s: WT BTK 0.57 μM, C481S BTK 0.80 μM). SNS-062 had good oral bioavailability in rat and dog (%F ≥ 40%) and a terminal half- life of 5 to 6 hours. 28 day repeat-dose toxicology studies in rat and dog showed that SNS-062 was well tolerated with continuous drug levels and at exposures (AUC∞) much greater than those achieved for ibrutinib. These results suggest that SNS-062 plasma concentrations may be achieved that provide prolonged inhibition of both WT and mutant BTK. Conclusions: SNS-062 is a noncovalent BTK inhibitor that also inhibits ITK but not EGFR. SNS-062 activity against both WT and mutant C481S BTK was similar, while ibrutinib activity was decreased 40 to 100-fold. SNS-062 has a nonclinical PK/safety profile that will likely provide SNS-062 plasma concentrations for sustained inhibition of both WT and mutant BTK. These results support clinical development of SNS-062 for B cell malignancies, including CLL with acquired resistance to ibrutinib. Citation Format: Minke E. Binnerts, Kevin L. Otipoby, Brian T. Hopkins, Tonika Bohnert, Stig Hansen, Gene Jamieson, Pamela A. Howland, Eric H. Bjerkholt, Deborah A. Thomas, Judith A. Fox, Adam R. Craig. SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C186.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
as完成签到 ,获得积分10
刚刚
刚刚
Sarah发布了新的文献求助10
2秒前
6秒前
Sarah完成签到,获得积分10
9秒前
科目三的应助被青岛采纳,获得10
18秒前
fossick2010完成签到 ,获得积分10
20秒前
21秒前
马静雨完成签到 ,获得积分10
24秒前
24秒前
无奈的枫叶完成签到 ,获得积分10
29秒前
青岛发布了新的文献求助10
29秒前
笑笑完成签到 ,获得积分10
33秒前
萧雨墨发布了新的文献求助10
35秒前
yf完成签到,获得积分10
36秒前
36秒前
37秒前
37秒前
传奇3的应助被科研通管家采纳,获得10
37秒前
打打的应助被科研通管家采纳,获得10
37秒前
CAOHOU的应助被科研通管家采纳,获得10
37秒前
寒冷的映冬完成签到,获得积分10
44秒前
47秒前
小林的火恐龙完成签到 ,获得积分10
1分钟前
风落完成签到 ,获得积分10
1分钟前
前方的菜鸟完成签到 ,获得积分10
1分钟前
molihuakai的应助被是绿子吖采纳,获得10
1分钟前
1分钟前
amiee发布了新的文献求助10
1分钟前
乐观寻芹完成签到,获得积分10
1分钟前
1分钟前
清爽的孤丝完成签到,获得积分10
1分钟前
1分钟前
儒雅的新儿完成签到,获得积分10
1分钟前
星野的应助被吴金菊采纳,获得10
1分钟前
汉堡包的应助被萧雨墨采纳,获得10
2分钟前
2分钟前
海洋球完成签到,获得积分10
2分钟前
2分钟前
Hyp完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21851985
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436236
关于科研通互助平台的介绍 2559951
邀请新用户注册赠送积分活动 2482818